60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

May 20, 2024 at 7:59 AM EDT
  • Long-term chronic fatigue syndrome (CFS) symptoms can be triggered by certain prior acute infections
  • Prominent researchers/clinicians in the tick-borne disease scientific community postulate that latent Babesia spp infections may trigger CFS symptoms
  • Planned study at North Carolina State College of Veterinary Medicine will assess whether Babesia spp parasites are present in samples from patients with chronic fatigue/neurologic symptoms by PCR
  • CDC estimates CFS affects 3.3 million Americans

WASHINGTON, May 20, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it will fund Babesia spp testing in chronic fatigue patient samples in a study to be conducted by North Carolina State College of Veterinary Medicine. Using PCR testing, the study will assess whether Babesia spp parasites are present in samples from patients with chronic fatigue symptoms who present with neurologic conditions. The study commences this month and is expected to run for 12 months.

Babesia spp is the parasite known to cause babesiosis, a potentially life-threatening disease in immunosuppressed patients. Babesiosis is a tick-borne illness steadily emerging in the United States. Approximately 47,000 cases per year may be present in the U.S. based on the observation of 476,000 Lyme infections, and an estimated babesiosis coinfection rate of 10 percent. The Centers for Disease Control and Prevention estimates CFS affects approximately 3.3 million Americans.

“We are pleased to provide support for this important study of babesiosis in patients with chronic fatigue syndrome symptoms,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoff Dow. “Increasingly, we are learning that babesiosis may be responsible for triggering any number of symptoms in patients presenting with certain very serious illnesses. This study will be a significant step toward adding to the medical community’s understanding of both babesiosis and chronic disease. This goal aligns well with the 60 Degrees Pharmaceutical mission.”

About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people.

60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com.

The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. The statements expressed herein are those of 60P and do not necessarily represent those of the U.S. Department of Defense or Department of the Army.

Cautionary Note Regarding Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Media Contact:
Sheila A. Burke
(484) 667-6330

Investor Contact:
Patrick Gaynes
(310) 989-5666

Primary Logo

Source: Sixty Degrees Pharmaceuticals